Exscientia

About Exscientia

Financials

Dated, source-cited figures. Estimates are marked.

Products by Exscientia

All products by Exscientia reviewed by our AI panel of experts.

ExscientiaAI Healthcare

AI-driven small-molecule design — now part of Recursion

Free7.4/10

How Our Review Panel Scores Exscientia

Six independent reviewer personalities assessed Exscientia's product on their own terms. They disagreed by 1.5 points — The Finance Lead was the hardest to convince, The Domain Strategist the most positive.

Averaged across 1 reviewed product in our catalog. Scores are out of 10.

Competitive Landscape

Who Exscientia competes with, and how they differ.

Insilico Medicine7.7/10

Runs an even more vertically integrated model -- generative chemistry plus its own clinical-stage pipeline (e.g. rentosertib in idiopathic pulmonary fibrosis) -- competing head-to-head with Exscientia's design-and-license strategy before the Recursion merger.

1 product reviewed on TopReviewed

I

Isomorphic Labs

DeepMind/Alphabet spinout using AlphaFold-derived structure prediction; raised $600M in March 2025 and signed nearly $3B in biobucks deals with Lilly and Novartis, competing for the same big-pharma co-development partnerships Exscientia pursued with Sanofi and BMS.

I

Insitro

Focuses on ML-driven target and biomarker discovery from large-scale genomic and wet-lab data rather than the small-molecule design engine that was Exscientia's core technology.

B

BenevolentAI

UK knowledge-graph-based peer that, unlike Exscientia's 2024 sale to Recursion, went through repeated restructurings and delisted from Euronext in March 2025, now operating as a private techbio around a narrower pipeline.

Company Timeline

Key milestones in Exscientia's history, with sources.

1. Nov 20, 2024Acquisition

   Merger with Recursion Pharmaceuticals completes

   The all-stock combination closed; the surviving Nasdaq-listed entity retained the Recursion name and ticker (RXRX), with Exscientia shareholders receiving approximately 26% of the combined company.

   marketscreener.com
2. Aug 8, 2024Milestone

   Recursion and Exscientia announce definitive merger agreement

   The two AI-driven drug discovery companies agreed to combine in an all-stock deal valued at roughly $688M, forming a combined "TechBio" company after a year of pipeline cuts and leadership departures at Exscientia.

   statnews.com
3. Jan 11, 2022Partnership

   EUR4.6B Sanofi collaboration for up to 15 oncology/immunology small-molecule drugs

   Exscientia and Sanofi announced a discovery collaboration in which Exscientia leads target discovery and candidate design and Sanofi takes candidates from preclinical development onward, worth EUR88M ($100M) upfront plus up to EUR4.6B ($5.2B) in milestones.

   labiotech.eu
4. Oct 1, 2021Milestone

   IPO on Nasdaq

   Exscientia priced its Nasdaq IPO at $22.00 per ADS, offering 13,850,000 ADSs for gross proceeds of approximately $304.7 million.

   sec.gov
5. May 19, 2021Partnership

   Expanded Bristol Myers Squibb collaboration

   Exscientia expanded its AI-driven small-molecule discovery collaboration with Bristol Myers Squibb across oncology and immunology, worth up to $50M upfront and $125M in near-to-mid-term milestones, with total potential deal value beyond $1.2B.

   businesswire.com
6. Apr 27, 2021Funding

   Series D -- $225M led by SoftBank Vision Fund 2

   Exscientia closed a $225 million Series D, with SoftBank committing an additional $300M equity option at the company's discretion (total potential $525M), to advance its AI-designed drug pipeline through clinical testing.

   businesswire.com
7. 2017Partnership

   Sanofi licensing deal for bispecific small-molecule metabolic disease drugs

   Exscientia and Sanofi sealed a roughly EUR250M licensing deal covering bispecific small-molecule candidates for metabolic disease; Sanofi in-licensed one of the resulting candidates in 2019.

   labiotech.eu